Abstract 3307
Background
All malignant mesothelioma (MM) patients progress after first-line therapy. We examined whether switch maintenance gemcitabine in patients, who did not show progression after first-line platinum-pemetrexed, could prolong time to disease progression.
Methods
NVALT19 was an open label, randomized phase II trial, conducted in The Netherlands. Main eligibility criteria were pathologically proven MM, ECOG-PS 0-2 and completion of 4-6 cycles of first-line platinum-pemetrexed without progression. Patients were randomized 1:1 between gemcitabine (1250 mg/m2 day 1 and 8 of 3 weekly schedule) or best supportive care (BSC). Gemcitabine was given until disease progression, severe toxicity or patient request for discontinuation. Primary endpoint was progression free survival (PFS) determined by local physician according to modified RECIST (mRECIST) or death in the intention-to-treat population. It was computed that 118 events would yield 90% power to detect an increase in PFS from median 3.5 months to median 6 months at 90% confidence level.
Results
Between March 2014 and February 2019, 130 patients were randomized, 65 in each arm. PFS was significantly longer with gemcitabine (median 6.2 months [range 4.6-8.7m]) than in the BSC arm (3.2 [2.8-4.2m]; hazard ratio 0.42; 95% confidence interval [CI], 0.28-0.63; p < 0.0001). The PFS probability at 12 months was 25% for Maintenance Gemcitabine (95% CI: 16.3 - 38.5%) and 3.3% for BSC (95% CI: 0.8 - 13%). Central revision of PFS, by a blinded radiologist, also showed significant benefit for gemcitabine (median 5.3 months [4.2-7.1m]) above BSC (2.8 [2.5-3.3m]; hazard ratio 0.42; 95% CI 0.28 to 0.62; p < 0.0001). Grade 3-4 adverse events (AE) occurred more in the gemcitabine arm (57% of patients) vs 13% in the BSC-arm. Neutropenia (22%), nausea (6%) and lung infection (5%) were most common treatment related grade III AE’s. Three patients (5%) experienced grade IV neutropenia. One patient died in the gemcitabine arm due to treatment related sepsis. Data on dose intensity will follow at ESMO 2019.
Conclusions
Switch maintenance gemcitabine after first-line chemotherapy significantly improves the PFS in malignant mesothelioma, with a manageable toxicity profile.
Clinical trial identification
NTR4132.
Editorial acknowledgement
Legal entity responsible for the study
Stichting NVALT studies.
Funding
Dutch Cancer Society and Stichting NVALT studies.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
6093 - BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy. SCAT Trial
Presenter: Bartomeu Massuti
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5626 - JIPANG study: Randomized Phase III Study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status
Presenter: Masahiro Tsuboi
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1522 - A Comprehensive Model of Genetic-Features Predicts Outcome of Personalized Adjuvant Treatment in Resected EGFR-mutant Stage II-IIIA NSCLC: Results from a Phase 3 Trial (CTONG 1104-ADJUVANT)
Presenter: Yi-Long Wu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2782 - Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC – Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial.
Presenter: Solange Peters
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1634 - Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: 10-year follow-up of West Japan Thoracic Oncology Group WJTOG0105
Presenter: Yoshitaka Zenke
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
4480 - Efficacy of durvalumab in patients with Stage III NSCLC who experience pneumonitis (PACIFIC)
Presenter: Johan Vansteenkiste
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
1920 - Differential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma
Presenter: Shaorong Yu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3721 - Randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC: long-term survival and toxicity analysis
Presenter: Ikuo Sekine
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
5386 - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy plus atezolizumab
Presenter: Davey Daniel
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies - Invited Discussant 1439PD, 1440PD and 1441PD
Presenter: Virginie Westeel
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast